[1] |
郭晖, 陈刚. Banff移植病理学诊断标准的起源、发展及对器官移植的推动作用[J]. 器官移植, 2021, 12(1): 15-22. DOI: 10.3969/j.issn.1674-7445.2021.01.003.GUO H, CHEN G. The origin and development of Banff classification on allograft pathology and its effects in promoting organ transplantation[J]. Organ Transplant, 2021, 12(1): 15-22. DOI: 10.3969/j.issn.1674-7445.2021.01.003.
|
[2] |
郭晖. 移植肾抗体介导的排斥反应的病理学[J]. 器官移植, 2021, 12(3): 262-271. DOI: 10.3969/j.issn.1674-7445. 2021.03.003.GUO H. Pathology of antibody-mediated rejection in renal allograft[J]. Organ Transplant, 2021, 12(3): 262-271. DOI: 10.3969/j.issn.1674-7445.2021.03.003.
|
[3] |
YOKOYAMA H, OKADA S, YAMADA Y, et al. Low-vacuum scanning electron microscopy may allow early diagnosis of human renal transplant antibody-mediated rejection[J]. Biomed Res, 2020, 41(2): 81-90. DOI: 10. 2220/biomedres.41.81.
|
[4] |
ONISHI H, OGUCHI H, SHINODA K, et al. Pathological analysis of early transplant glomerulopathy in renal allografts using low-vacuum scanning electron microscopy[J]. Nephron, 2020, 144 (Suppl 1): 71-78. DOI: 10.1159/000512136.
|
[5] |
MOROZUMI K, TAKEDA A, OTSUKA Y, et al. Reviewing the pathogenesis of antibody-mediated rejection and renal graft pathology after kidney transplantation[J]. Nephrology (Carlton), 2016, 21 (Suppl 1): 4-8. DOI: 10.1111/nep.12777.
|
[6] |
武忠弼. 超微病理诊断学[M]. 上海: 上海科学技术出版社, 2003.
|
[7] |
史景泉, 陈意生, 卞修武. 超微病理学[M]. 北京: 化学工业出版社, 2005.
|
[8] |
HAAS M. Evolving criteria for the diagnosis of antibody-mediated rejection in renal allografts[J]. Curr Opin Nephrol Hypertens, 2018, 27(3): 137-143. DOI: 10.1097/MNH.0000000000000398.
|
[9] |
CHAPMAN JR, WAVAMUNNO M, O'CONNELL PJ, et al. Unravelling the connections between donor specific antibodies and renal allograft pathology[J]. Clin Transpl, 2013: 361-365. http://europepmc.org/abstract/med/25095530
|
[10] |
HAAS M. Pathology of C4d-negative antibody-mediated rejection in renal allografts[J]. Curr Opin Organ Transplant, 2013, 18(3): 319-326. DOI: 10.1097/MOT.0b013e32835d4daf.
|
[11] |
PAPADIMITRIOU JC, DRACHENBERG CB, RAMOS E, et al. Antibody-mediated allograft rejection: morphologic spectrum and serologic correlations in surveillance and for cause biopsies[J]. Transplantation, 2013, 95(1): 128-136. DOI: 10.1097/TP.0b013e3182777f28.
|
[12] |
SNIJDERS MLH, VAROL H, VAN DER ZWAN M, et al. Molecular analysis of renal allograft biopsies: where do we stand and where are we going?[J]. Transplantation, 2020, 104(12): 2478-2486. DOI: 10.1097/TP.0000000000003220.
|
[13] |
KIM MY, BRENNAN DC. Therapies for chronic allograft rejection[J]. Front Pharmacol, 2021, 12: 651222. DOI: 10.3389/fphar.2021.651222.
|
[14] |
SOLAR-CAFAGGI D, MARINO L, URIBE-URIBE N, et al. Antibody-mediated rejection in the Banff classifications of 2007 and 2017: a comparison of renal graft loss prediction capability[J]. Transpl Immunol, 2018, 51: 40-44. DOI: 10.1016/j.trim.2018.08.008.
|
[15] |
HAAS M. The revised (2013) Banff classification for antibody-mediated rejection of renal allografts: update, difficulties, and future considerations[J]. Am J Transplant, 2016, 16(5): 1352-1357. DOI: 10.1111/ajt.13661.
|
[16] |
MONGA G, MAZZUCCO G, NOVARA R, et al. Intertubular capillary changes in kidney allografts: an ultrastructural study in patients with transplant glomerulopathy[J]. Ultrastruct Pathol, 1990, 14(3): 201-209. DOI: 10.3109/01913129009076124.
|
[17] |
MONGA G, MAZZUCCO G, MESSINA M, et al. Intertubular capillary changes in kidney allografts: a morphologic investigation on 61 renal specimens[J]. Mod Pathol, 1992, 5(2): 125-130.
|
[18] |
FILIPPONE EJ, MCCUE PA, FARBER JL. Transplant glomerulopathy[J]. Mod Pathol, 2018, 31(2): 235-252. DOI: 10.1038/modpathol.2017.123.
|
[19] |
VAZQUEZ MARTUL E. The pathology of renal transplants[J]. Rev Esp Patol, 2018, 51(2): 110-123. DOI: 10.1016/j.patol.2017.10.001.
|
[20] |
LOUPY A, HAAS M, SOLEZ K, et al. The Banff 2015 kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology[J]. Am J Transplant, 2017, 17(1): 28-41. DOI: 10.1111/ajt.14107.
|
[21] |
LOUPY A, HAAS M, ROUFOSSE C, et al. The Banff 2019 kidney meeting report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection[J]. Am J Transplant, 2020, 20(9): 2318-2331. DOI: 10.1111/ajt.15898.
|
[22] |
HAAS M, LOUPY A, LEFAUCHEUR C, et al. The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials[J]. Am J Transplant, 2018, 18(2): 293-307. DOI: 10.1111/ajt.14625.
|
[23] |
DE SERRES SA, NOËL R, CÔTÉ I, et al. 2013 Banff criteria for chronic active antibody-mediated rejection: assessment in a real-life setting[J]. Am J Transplant, 2016, 16(5): 1516-1525. DOI: 10.1111/ajt.13624.
|
[24] |
SENEV A, COEMANS M, LERUT E, et al. Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: clinical presentation and implications for outcome[J]. Am J Transplant, 2019, 19(3): 763-780. DOI: 10.1111/ajt.15074.
|
[25] |
SABLIK KA, CLAHSEN-VAN GRONINGEN MC, LOOMAN CWN, et al. Chronic-active antibody-mediated rejection with or without donor-specific antibodies has similar histomorphology and clinical outcome - a retrospective study[J]. Transpl Int, 2018, 31(8): 900-908. DOI: 10.1111/tri.13154.
|
[26] |
PARAJULI S, REDFIELD RR, GARG N, et al. Clinical significance of microvascular inflammation in the absence of anti-HLA DSA in kidney transplantation[J]. Transplantation, 2019, 103(7): 1468-1476. DOI: 10.1097/TP.0000000000002487.
|
[27] |
WANG J, LI X, WU X, et al. Gut microbiota alterations associated with antibody-mediated rejection after kidney transplantation[J]. Appl Microbiol Biotechnol, 2021, 105(6): 2473-2484. DOI: 10.1007/s00253-020-11069-x.
|
[28] |
CLOTET-FREIXAS S, MCEVOY CM, BATRUCH I, et al. Extracellular matrix injury of kidney allografts in antibody-mediated rejection: a proteomics study[J]. J Am Soc Nephrol, 2020, 31(11): 2705-2724. DOI: 10.1681/ASN.2020030286.
|